Floatz logo

Sofosbuvir

Liver Cancer

M.D. Anderson Cancer CenterSmall moleculePhase 4 / ApprovedActive
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
65/ 100

Competitive context

111 Active assets in the Liver Cancer cohort.

Asset / SponsorPhaseRating
Bxcl501
Uppsala University Hospital
Phase 4BBB
Inno-206
Shanghai Zhongshan Hospital
Phase 4BB
Eloxatin
Sun Yat-sen University
Phase 3BB
SUFENTANYL
The Second Affiliated Hospital of Chongqing Medical University
Phase 4BB
Idarubicine
Second Affiliated Hospital of Guangzhou Medical University
Phase 3BB

View all 50 →

Same molecule, other indications

Sofosbuvir is also rated in:

hepatitis C virus infectionDormant
A
Indicative ·
82 / 100
View asset →
chronic hepatitis C virus infectionDormant
A
Indicative ·
81 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →